Press Releases Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
40.98 ^USD	-1.09%		+7.42%	-10.85%

Apr. 30	Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	CI
Apr. 18	Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology	Apr. 29	GL
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024	Apr. 24	GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	Apr. 16	GL
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing	Apr. 01	GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	Mar. 25	GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	Mar. 25	AQ
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	Mar. 11	GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	Mar. 11	AQ
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences	Mar. 06	GL
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update	Feb. 22	GL
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update	Feb. 22	AQ
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan	Feb. 22	GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	Feb. 08	GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	Feb. 08	AQ
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome	Feb. 08	AQ
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome	Feb. 07	GL
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome	Feb. 07	AQ
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024	Jan. 31	GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	Jan. 15	AQ
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	Jan. 12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Press Releases

Filters